Breast cancer: The upgraded role of HER-3 and HER-4

International Journal of Biochemistry and Cell Biology

Volumn 39, Issue 5, 2007, Pages 851-856

  Karamouzis, Michalis V ^a   Badra, Filitsa A ^b   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b THRIASIO GENERAL HOSPITAL   (Greece)

Author keywords

Breast cancer; ErbB receptors; HER 3; HER 4

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LIGAND; NEU DIFFERENTIATION FACTOR; TRASTUZUMAB;

BREAST CANCER; DIMERIZATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; PATHOGENESIS; SHORT SURVEY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MODELS, BIOLOGICAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 34147113352     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2006.11.017     Document Type: Short Survey

References (23)

1. Abd El-Rehim D.M., Pinder S.E., Paish C.E., Bell J.A., Rampaul R.S., Blamey R.W., et al. Expression and coexpression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. British Journal of Cancer 91 (2004) 1532-1542
2. Atalay G., Cardoso F., Awada A., and Piccart M.J. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Annals of Oncology 14 (2003) 1346-1363
3. Badra F.A., Karamouzis M.V., Ravazoula P., Likaki-Karatza E., Tzorakoleftherakis E., Koukouras D., et al. Non-palpable breast carcinomas: Correlation of mammographically detected malignant-appearing microcalcifications and epidermal growth factor receptor (EGFR) family expression. Cancer Letters 244 (2006) 34-41
4. Barnes C.J., Khavari S., Boland G.P., Cramer A., Knox W.F., and Bundred N.J. Absence of HER-4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clinical Cancer Research 11 (2005) 2163-2168
5. Citri A., Skaria K.B., and Yarden Y. The deaf and the dumb: The biology of ErbB-2 and ErbB-3. Experimental Cell Research 284 (2003) 54-65
6. Citri A., and Yarden Y. EGF-ERBB signalling: Towards the systems level. Nature Reviews in Molecular and Cellular Biology 7 (2006) 505-516
7. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thürlimann B., Senn H.J., et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Annals of Oncology 16 (2005) 1569-1583
8. Harris R.C., Chung E., and Coffey R.J. EGF receptor ligands. Experimental Cell Research 284 (2003) 2-13
9. Hayes D.F. Prognostic and predictive factors for breast cancer: Translating technology to oncology. Journal of Clinical Oncology 23 (2005) 1596-1597
10. Karamouzis M.V., Likaki-Karatza E., Ravazoula P., Badra F.A., Koukouras D., Tzorakoleftherakis E., et al. Non-palpable breast carcinomas: Correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors. International Journal of Cancer 102 (2002) 86-90
11. Marshall C., Blackburn E., Clark M., Humphreys S., and Gullick W.J. Neuregulins 1-4 are expressed in the cytoplasm or nuclei of ductal carcinoma (in situ) of the human breast. Breast Cancer Research and Treatment 96 (2006) 163-168
12. Menendez J.A., Mehmi I., and Lupu R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. Journal of Clinical Oncology 24 (2006) 3735-3746
13. Mosesson Y., and Yarden Y. Oncogenic growth factor receptors: Implications for signal transduction therapy. Seminars in Cancer Biology 14 (2004) 262-270
14. Muraoka-Cook R.S., Caskey L.S., Sandahl M.A., Hunter D.M., Husted C., Strunk K.E., et al. Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1. Molecular and Cellular Biology 26 (2006) 6412-6424
15. Naresh A., Long W., Vidal G.A., Wimley W.C., Marrero L., Sartor C.I., et al. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Research 66 (2006) 6412-6420
16. Nelson M.H., and Dodler C.R. Lapatinib: A novel dual tyrosine kinase inhibitor with activity in solid tumors. Annals of Pharmacotherapy 40 (2006) 261-269
17. Roy Y., and Perez E.A. New therapies in the treatment of breast cancer. Seminars in Oncology 33 3 Suppl. 9 (2006) S3-S8
18. Tanos B., and Pendergast A.M. ABL tyrosine kinase regulates endocytosis of the epidermal growth factor receptor. Journal of Biological Chemistry (2006). http://www.jbc.org/cgi/doi/10.1074/jbc.M603126200 http://www.jbc.org/cgi/doi/10.1074/jbc.M603126200.
19. Tsai M.S., Shamon-Taylor L.A., Mehmi I., Tang C.K., and Lupu R. Blockage of heregulin expression inhibits tumorigennicity and metastasis of breast cancer. Oncogene 22 (2003) 761-768
20. Wiseman S.M., Makretsov N., Nielsen T.O., Gilks B., Yorida E., Cheang M., et al. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative effect on breast carcinoma survival. Cancer 103 (2004) 1770-1777
21. Witton C.J., Reeves J.R., Going J.J., Cooke T.G., and Bartlett J.M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. Journal of Pathology 200 (2003) 290-297
22. Xu H., Yu Y., Marciniak D., Rishi A.K., Sarkar F.H., Kucuk O., et al. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Molecular Cancer Therapeutics 4 (2005) 435-442
23. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nature Reviews in Molecular and Cellular Biology 2 (2001) 127-137